Milford Funds Ltd. purchased a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) in the 4th quarter, Holdings Channel reports. The fund purchased 269,420 shares of the conglomerate’s stock, valued at approximately $61,676,000. Danaher accounts for about 1.2% of Milford Funds Ltd.’s investment portfolio, making the stock its 29th biggest position.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Norges Bank bought a new position in shares of Danaher during the 4th quarter valued at approximately $2,177,106,000. Viking Global Investors LP grew its stake in shares of Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after acquiring an additional 2,455,994 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Danaher by 104.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock valued at $991,923,000 after acquiring an additional 2,216,789 shares during the period. Generation Investment Management LLP grew its stake in shares of Danaher by 34.0% during the 3rd quarter. Generation Investment Management LLP now owns 6,654,666 shares of the conglomerate’s stock valued at $1,319,354,000 after acquiring an additional 1,689,020 shares during the period. Finally, Capital International Investors grew its stake in shares of Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after acquiring an additional 1,487,768 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Trading Down 0.5%
DHR stock opened at $179.95 on Friday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. The company has a market capitalization of $127.37 billion, a price-to-earnings ratio of 34.81, a PEG ratio of 2.41 and a beta of 0.81. The business has a 50 day simple moving average of $180.93 and a two-hundred day simple moving average of $204.78.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is presently 30.95%.
Wall Street Analyst Weigh In
DHR has been the subject of a number of recent research reports. Citigroup initiated coverage on Danaher in a research note on Tuesday, May 26th. They set a “buy” rating and a $230.00 price objective for the company. Wall Street Zen downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Robert W. Baird cut their price objective on Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Piper Sandler initiated coverage on Danaher in a research note on Thursday. They set a “neutral” rating and a $200.00 price objective for the company. Finally, Royal Bank Of Canada initiated coverage on Danaher in a research note on Thursday, May 14th. They set an “outperform” rating and a $200.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $233.61.
Get Our Latest Research Report on Danaher
More Danaher News
Here are the key news stories impacting Danaher this week:
- Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
- Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
- Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?
About Danaher
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Recommended Stories
- Five stocks we like better than Danaher
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
